Chase Investment Counsel’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Chase Investment Counsel’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Buy	+2,400	New	+$202K	0.05%	124
2025 Q4	–	Sell	-8,980	Closed	-$534K	–	133
2025 Q3	$534K	Hold	8,980	–	–	0.16%	96
2025 Q2	$411K	Hold	8,980	–	–	0.13%	108
2025 Q1	$432K	Hold	8,980	–	–	0.16%	98
2024 Q4	$454K	Hold	8,980	–	–	0.15%	99
2024 Q3	$572K	Sell	8,980 -1,555	-15%	-$100K	0.19%	82
2024 Q2	$624K	Sell	10,535 -1,520	-13%	-$84.1K	0.22%	88
2024 Q1	$693K	Hold	12,055	–	–	0.26%	87
2023 Q4	$687K	Hold	12,055	–	–	0.3%	80
2023 Q3	$578K	Sell	12,055 -4,155	-26%	-$213K	0.29%	78
2023 Q2	$843K	Hold	16,210	–	–	0.43%	60
2023 Q1	$878K	Buy	+16,210	New	+$915K	0.49%	59
2022 Q1	–	Sell	-22,285	Closed	-$1.81M	–	115
2021 Q4	$1.81M	Hold	22,285	–	–	0.72%	48
2021 Q3	$2.12M	Hold	22,285	–	–	0.91%	43
2021 Q2	$2.19M	Hold	22,285	–	–	0.91%	44
2021 Q1	$1.86M	Sell	22,285 -13,600	-38%	-$1.28M	0.85%	51
2020 Q4	$3.1M	Hold	35,885	–	–	1.37%	31
2020 Q3	$2.51M	Hold	35,885	–	–	1.25%	32
2020 Q2	$2.6M	Buy	+35,885	New	+$2.29M	1.32%	26
2019 Q4	–	Sell	-46,396	Closed	-$1.97M	–	109
2019 Q3	$1.97M	Hold	46,396	–	–	1.01%	39
2019 Q2	$2.4M	Hold	46,396	–	–	1.22%	34
2019 Q1	$2.57M	Hold	46,396	–	–	1.32%	32
2018 Q4	$1.95M	Hold	46,396	–	–	1.16%	32
2018 Q3	$3.23M	Hold	46,396	–	–	1.67%	23
2018 Q2	$2.65M	Hold	46,396	–	–	1.43%	30
2018 Q1	$2.55M	Hold	46,396	–	–	1.32%	33
2017 Q4	$2.6M	Hold	46,396	–	–	1.37%	33
2017 Q3	$2.84M	Hold	46,396	–	–	1.49%	32
2017 Q2	$2.48M	Hold	46,396	–	–	1.2%	35
2017 Q1	$2.24M	Hold	46,396	–	–	1.08%	35
2016 Q4	$1.85M	Hold	46,396	–	–	0.92%	40
2016 Q3	$2.25M	Buy	+46,396	New	+$2.2M	0.99%	38

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return

KFS

Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return

Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

ATPW

Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Chase Investment Counsel's BIB Position: Q2 2026 in Review

Chase Investment Counsel opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2026: 2,400 shares worth $241K. The stake represents 0.05% of the portfolio and ranks #124 among its holdings. This is a return to the name: Chase Investment Counsel previously reported a position in BIB as recently as Q3 2025.

Chase Investment Counsel first reported a position in BIB in Q3 2016 and has held it in 32 quarters since. The position peaked at $3.23M in Q3 2018. 20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

Chase Investment Counsel held 2,400 shares of ProShares Ultra NASDAQ Biotechnology worth $241K as of Q2 2026.
ProShares Ultra NASDAQ Biotechnology was a new Chase Investment Counsel position in Q2 2026.
ProShares Ultra NASDAQ Biotechnology made up 0.05% of Chase Investment Counsel's portfolio in Q2 2026, its #124 holding.
Chase Investment Counsel first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2016 and has held it in 32 quarters since.
Chase Investment Counsel's ProShares Ultra NASDAQ Biotechnology position peaked at $3.23M in Q3 2018.
20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Chase Investment Counsel's 13F filing for Q2 2026, filed 6 Aug 2026.